By Lori Solomon HealthDay ReporterTUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

BELLY fat increases your risk of the skin condition psoriasis, a study warns. Psoriasis, which affects one in 50 people – ...

STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study, ...

Struggling with hair loss, breakage, or thinning hair? Good news: There are plenty of hair growth products that can help ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Discover why your skin develops scaling patches, from common dry skin to medical conditions requiring treatment, plus ...